Response to treatment
breast cancer
ADVERSE EVENTS, RESIDUAL CANCER, BREAST CANCER
Pathological response according to RCB classification is presented in Table Pathological complete response to neoadjuvant breast cancer treatment and serious adverse events during treatment. Patients in both arms received a standard neoadjuvant treatment regimen with delta-tocotrienol added in the intervention group.Pathological response evaluated by histopathological assessment of the surgically removed tissue with graduation according to the Residual Cancer Burden (RCB) Calculator (MD Anderson